Enrico Sebastiani

Dr. Enrico Sebastiani

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2023 in Cancer Research
Verified
Journal Article
Closed access
PDF file
FBFrancesca Broso
Francesca Broso
PGPamela Gatto
Pamela Gatto
VSViktoryia Sidarovich
Viktoryia Sidarovich
CAChiara Ambrosini
Chiara Ambrosini
VSVeronica De Sanctis
Veronica De Sanctis
AQAlessandro Quattrone
Alessandro Quattrone
Neuroblastoma (NB) is an aggressive childhood tumor, with high-risk cases having a 5-year overall survival probability of approximately 50%. The multimodal therapeutic approach for NB includes treatment with the retinoid isotretinoin (13-cis retinoic acid; 13cRA), which is used in the post-consolidation phase as an antiproliferation and prodifferentiation agent to minimize residual disease and prevent relapse. Through small-molecule screening, we identified isorhamnetin (ISR) as a synergistic compound with 13cRA in inhibiting up to 80% of NB cell viability. The synergistic effect was accompanied by a marked increase in the expression of the adrenergic receptor α1B (ADRA1B) gene. Genetic knockout of ADRA1B or its specific blockade using α1/α1B adrenergic antagonists led to selective sensitization of MYCN-amplified NB cells to cell viability reduction and neural differentiation induced by 13cRA, thus mimicking ISR activity. Administration of doxazosin, a safe α1-antagonist used in pediatric patients, in combination with 13cRA in NB xenografted mice exerted marked control of tumor growth, whereas each drug alone was ineffective. Overall, this study identified the α1B adrenergic receptor as a pharmacologic target in NB, supporting the evaluation of adding α1-antagonists to the post-consolidation therapy of NB to more efficiently control residual disease. Significance: Targeting α-adrenergic receptors synergizes with isotretinoin to suppress growth and to promote differentiation of neuroblastoma, revealing a combinatorial approach for more effective management of the disease and prevention of relapse.

19 February 2026 in Infectious Agents and Cancer
Verified
Journal Article
Open access
PDF file
MCMarco Cascella
Marco Cascella
CPCesare Pane
Cesare Pane
MPMarcello Di Pumpo
Marcello Di Pumpo
ESEnrico Sebastiani
Enrico Sebastiani
MBMartino Bussa
Martino Bussa
VGVincenza Granata
Vincenza Granata
Digital health technologies (DHTs), including digital therapeutics (DTx), are revolutionizing patient care by enabling the prevention, management, and trea

15 August 2023
Verified
Other
Open access
PDF file
FBFrancesca Broso
Francesca Broso
PGPamela Gatto
Pamela Gatto
VSViktoryia Sidarovich
Viktoryia Sidarovich
CAChiara Ambrosini
Chiara Ambrosini
VSVeronica De Sanctis
Veronica De Sanctis
AQAlessandro Quattrone
Alessandro Quattrone
Supplementary Figures from S1 to S23 and Supplementary tables from S1 to S3

24 November 2025
Verified
Other
Open access
FBFrancesca Broso
Francesca Broso
PGPamela Gatto
Pamela Gatto
VSViktoryia Sidarovich
Viktoryia Sidarovich
CAChiara Ambrosini
Chiara Ambrosini
VSVeronica De Sanctis
Veronica De Sanctis
AQAlessandro Quattrone
Alessandro Quattrone
Neuroblastoma (NB) is an aggressive childhood tumor, with high-risk cases having a 5-year overall survival probability of approximately 50%. The multimodal therapeutic approach for NB includes treatment with the retinoid isotretinoin (13-cis retinoic acid; 13cRA), which is used in the post-consolidation phase as an antiproliferation and prodifferentiation agent to minimize residual disease and prevent relapse. Through small-molecule screening, we identified isorhamnetin (ISR) as a synergistic compound with 13cRA in inhibiting up to 80% of NB cell viability. The synergistic effect was accompanied by a marked increase in the expression of the adrenergic receptor α1B (ADRA1B) gene. Genetic knockout of ADRA1B or its specific blockade using α1/α1B adrenergic antagonists led to selective sensitization of MYCN-amplified NB cells to cell viability reduction and neural differentiation induced by 13cRA, thus mimicking ISR activity. Administration of doxazosin, a safe α1-antagonist used in pediatric patients, in combination with 13cRA in NB xenografted mice exerted marked control of tumor growth, whereas each drug alone was ineffective. Overall, this study identified the α1B adrenergic receptor as a pharmacologic target in NB, supporting the evaluation of adding α1-antagonists to the post-consolidation therapy of NB to more efficiently control residual disease.Significance:Targeting α-adrenergic receptors synergizes with isotretinoin to suppress growth and to promote differentiation of neuroblastoma, revealing a combinatorial approach for more effective management of the disease and prevention of relapse.

28 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MCMarco Cascella
Marco Cascella
CPCesare Pane
Cesare Pane
MPMarcello Di Pumpo
Marcello Di Pumpo
ESEnrico Sebastiani
Enrico Sebastiani
MBMartino Bussa
Martino Bussa
VGVincenza Granata
Vincenza Granata
Digital health technologies (DHTs), including digital therapeutics (DTx), are revolutionizing patient care by enabling the prevention, management, and treatment of medical conditions. These tools comprise care delivery mobile applications, wearable devices, and cloud platforms for capturing real-time data and enabling remote monitoring. DTx also encompasses artificial intelligence (AI) and machine learning algorithms, as well as AI agents and digital twins (DTs) for clinical decision-making and predictive analytics. Evidence supports the effectiveness of DHT strategies across different clinical fields. For example, wearable and remote patient monitoring technologies enable continuous assessment and personalized feedback in cardiology and neurology. Additionally, AI-enabled devices are mostly implemented for continuous monitoring of glucose levels. However, several key challenges remain. Persistent gender and social biases in datasets and algorithms raise ethical concerns, particularly for underrepresented groups and pediatric populations. Mitigation strategies include regulatory frameworks, explainable AI, and trustworthy AI ecosystems. This narrative review synthesizes current evidence, highlights implementation barriers, and proposes recommendations to enhance inclusivity, interoperability, and real-world evaluation of these technologies. Applications of DHT in animals within the one digital health framework are also discussed.

8 August 2023
Verified
Other
Open access
FBFrancesca Broso
Francesca Broso
PGPamela Gatto
Pamela Gatto
VSViktoryia Sidarovich
Viktoryia Sidarovich
CAChiara Ambrosini
Chiara Ambrosini
VSVeronica De Sanctis
Veronica De Sanctis
AQAlessandro Quattrone
Alessandro Quattrone
Neuroblastoma (NB) is an aggressive childhood tumor, with high-risk cases having a 5-year overall survival probability of approximately 50%. The multimodal therapeutic approach for NB includes treatment with the retinoid isotretinoin (13-cis retinoic acid; 13cRA), which is used in the post-consolidation phase as an antiproliferation and prodifferentiation agent to minimize residual disease and prevent relapse. Through small-molecule screening, we identified isorhamnetin (ISR) as a synergistic compound with 13cRA in inhibiting up to 80% of NB cell viability. The synergistic effect was accompanied by a marked increase in the expression of the adrenergic receptor α1B (ADRA1B) gene. Genetic knockout of ADRA1B or its specific blockade using α1/α1B adrenergic antagonists led to selective sensitization of MYCN-amplified NB cells to cell viability reduction and neural differentiation induced by 13cRA, thus mimicking ISR activity. Administration of doxazosin, a safe α1-antagonist used in pediatric patients, in combination with 13cRA in NB xenografted mice exerted marked control of tumor growth, whereas each drug alone was ineffective. Overall, this study identified the α1B adrenergic receptor as a pharmacologic target in NB, supporting the evaluation of adding α1-antagonists to the post-consolidation therapy of NB to more efficiently control residual disease.Significance:Targeting α-adrenergic receptors synergizes with isotretinoin to suppress growth and to promote differentiation of neuroblastoma, revealing a combinatorial approach for more effective management of the disease and prevention of relapse.